Citations

Mayo Clinic

Showing 10 of 108599 citations.

Classification and Predictors of Right Ventricular Functional Recovery in Pulmonary Arterial Hypertension
Rischard, Franz , Bernardo, Roberto J. , Vanderpool, Rebecca , Kwon, Deborah , Acharya, Tushar , Park, Margaret , Katrynuik, Austin, Insel, Michael , Kubba, Saad , Badagliacca, Roberto , Larive, A. Brett, Naeije, Robert , Garcia, Joe G. N. , Beck, Gerald J. , Erzurum, Serpil C. , Hill, Nicholas S. , Wilcox, Jennifer , Rischard, Franz P , Vanderpool, Rebecca R , Kwon, Deborah H , Park, Margaret M , Frantz, Robert P , Hemnes, Anna , Hill, Nicholas S , Horn, Evelyn M , Leopold, Jane A , Rosenzweig, Erika B , Tang, W H Wilson , Wilcox, Jennifer D , Frantz, Robert P. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rosenzweig, Erika B. , Tang, W.H. Wilson

Circulation: Heart Failure | September 4, 2023 | Volume: 16 | Issue: 10 | Pages: No page available

10.1161/circheartfailure.123.010555 | PMID 37664964 Get It

Background: Normative changes in right ventricular (RV) structure and function have not been characterized in the context of treatment-associated functional recovery (RV functional recovery [RVFnRec]). The aim of this study is to assess the clinical relevance of a proposed RVFnRec definition. Methods: We evaluated 63 incident patients with pulmonary arterial hypertension by right heart catheterization and cardiac magnetic resonance imaging at diagnosis and cardiac magnetic resonance imaging and invasive cardiopulmonary exercise testing following treatment (≈11 months). Sex, age, ethnicity matched healthy control subjects (n=62) with 1-time cardiac magnetic resonance imaging and noninvasive cardiopulmonary exercise testing were recruited from the PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) project. We examined therapeutic cardiac magnetic resonance imaging changes relative to the evidence-based peak oxygen consumption (VO 2peak )>15 mL/(kg·min) to define RVFnRec by receiver operating curve analysis. Afterload was measured as mean pulmonary artery pressure, resistance, compliance, and elastance. Results: A drop in RV end-diastolic volume of −15 mL best defined RVFnRec (area under the curve, 0.87; P =0.0001) and neared upper 95% CI RV end-diastolic volume of controls. This cutoff was met by 22 out of 63 (35%) patients which was reinforced by freedom from clinical worsening, RVFnRec 1 out of 21 (5%) versus no RVFnRec 17 out of 42, 40% (log-rank P =0.006). A therapy-associated increase of 0.8 mL/mm Hg in compliance had the best predictive value of RVFnRec (area under the curve, 0.76; [95% CI, 0.64–0.88]; P =0.001). RVFnRec patients had greater increases in stroke volume, and cardiac output at exercise. Conclusions: RVFnRec defined by RV end-diastolic volume therapeutic decrease of −15 mL predicts exercise capacity, freedom from clinical worsening, and nears normalization. A therapeutic improvement of compliance is superior to other measures of afterload in predicting RVFnRec. RVFnRec is also associated with increased RV output reserve at exercise.
Editorial: penetration of food protein through the oesophageal mucosa ‐ is this where EoE starts? Authors' reply
Ravi, Anupama, Katzka, David A.

Alimentary Pharmacology & Therapeutics | September 3, 2023 | Volume: 53 | Issue: 3 | Pages: 449-449

10.1111/apt.16223 | PMID 33428253 Get It

LINKED CONTENTThis article is linked to Ravi et al and Uchida & Dougan papers. To view these articles, visit https://doi.org/10.1111/apt.16180 and https://doi.org/10.1111/apt.16205
Mucosal penetration and clearance of gluten and milk antigens in eosinophilic oesophagitis
Ravi, Anupama, Marietta, Eric, Alexander, Jeffrey A. , Peterson, Kathryn A. , Lavey, Crystal, Geno, Debra M., Murray, Joseph A. , Katzka, David A. , Marietta, Eric V., Peterson, Kathryn , Murray, J A

Alimentary Pharmacology & Therapeutics | September 3, 2023 | Volume: 53 | Issue: 3 | Pages: 410-417

10.1111/apt.16180 | PMID 33264440 Get It

SummaryBackgroundThe Th2 allergic pathway in eosinophilic oesophagitis (EoE) responds to food antigen exposure.AimTo compare the presence and temporal pattern of food antigen penetration in oesophageal mucosa in active and inactive EoE and controlsMethodsThirty‐two patients with EoE (20 active) and 10 controls were asked to eliminate all wheat and/or dairy 12, 24, 48, 72 or 96 hours before endoscopy. Immunostaining on endoscopic biopsies was performed for gliadin, casein and whey.ResultsGluten, casein and whey were detected by positive staining in 17/32 (53.1%), 21/32 (65.6%), and 30/32 (92.0%) of patients, respectively. In active vs inactive EoE, 70.0% vs 25.0% (P < 0.05), 80.0% vs 41.5%, and 90.0% vs 90.9% patients had detectable gliadin, casein and whey, respectively. Casein and whey (20.0% and 100%, respectively) but not gliadin, were present in controls. The gliadin staining density was greater in active compared to inactive disease at ≤ 24 vs >24 hours after exposure (P = 0.05) but no differences were detected when comparing active and inactive patients for casein and whey. There was greater staining density for whey than casein for all patients at ≤24 hours (mean 2.14 ± 0.91 and 1.07 ± 1.33, P = 0.02). In active EoE, IgG4 was present in 14/20 compared to one inactive patient.ConclusionThe oesophageal epithelium is selectively permeable and has relatively long dwell times for food antigens known to trigger EoE. The precise mechanism of antigen‐specific mucosal entry and the factors that determine the induction or effector trigger of the Th2 pathway activation merit further study.
The significance of histological activity measurements in immune checkpoint inhibitor colitis
Pai, Rish K. , Pai, Reetesh K., Pai, Reetesh K., Brown, Ian , Choi, Won‐Tak , Kumarasinghe, M. Priyanthi , Gunawardena, Dilini , Kim, Baek Hui, Friedman, Mark , Ghayouri, Masoumeh, Lauwers, Gregory Y. , Brown, Ian S , Pai, Reetesh K., Pai, Reetesh K., Schaeffer, David F. , Farnell, David

Alimentary Pharmacology & Therapeutics | September 3, 2023 | Volume: 53 | Issue: 1 | Pages: 150-159

10.1111/apt.16142 | PMID 33146440 Get It

SummaryBackgroundColitis is a significant complication of immune checkpoint inhibitors (ICI). Currently, clinical and endoscopic severity are used to guide therapy.AimsTo investigate associations between clinical, endoscopic, and histological features with outcomesMethodsWe identified 149 patients from seven institutions with biopsy‐proven ICI colitis. Biopsies were evaluated for histological features including the Geboes score, and the Robarts histopathological index (RHI) was calculated. Clinical, endoscopic, and histological data were tested for associations with biological use and adverse colitis outcomes (biological‐refractory colitis, colectomy or death from colitis).ResultsThree mutually exclusive histological patterns were identified: acute colitis, chronic active colitis and microscopic colitis. Microscopic colitis was associated with older age (68.5 vs 61 years for acute colitis pattern, P = 0.02) and longer time to colitis (5.5 vs 3 months for the other patterns, P = 0.05). Biological use was associated with earlier time to colitis (2 vs 3 months, P = 0.04) and higher RHI (18 vs 12, P = 0.007). On multivariate analysis, RHI ≥14 was associated with biological use with an odds ratio of 4.5 (95% CI 1.4‐13.8; P = 0.01). Adverse colitis outcomes were associated with shorter time to colitis (2 vs 3 months, P = 0.008) and higher RHI (24 vs 14, P = 0.001). On multivariate analysis, RHI ≥24 was associated with adverse colitis outcomes with an odds ratio 9.5 (95% CI 2.1‐42.3 P = 0.003).ConclusionHistological activity as measured by RHI is the only factor independently associated with biological use and adverse colitis outcomes. Prospective studies are needed to validate these findings to determine if histological activity should be incorporated into therapeutic algorithms.
Coronary artery dissection and Myocarditis caused by Eosinophilic granulomatosis with polyangiitis (EGPA): A case report
Vivek, Vidhyalakshmy, Yadav, Sumeet Kumar, Mir, Mikael , Jain, Shika, Jama, Abbas B., Trivedi, Setu , Xu, Qiping , Meda, Namratha Seetharam , Ali, Syed F. , Hassan, Esraa , Attallah, Noura , Patnaik, Harsha, Obulareddy, Sri Usha Jeevani, Rauf, Ibtisam , Korsapati, Aishwarya Reddy, Khan, Syed Anjum , Jain, Nitesh , Bawaadam, Hasnain , Korsapati, Hariprasad R, Khan, Syed A, Jain, Nitesh K, Korsapati, Hariprasad Reddy , Jama, Abbas B, Ali, Syed, Khedr, Anwar , Hassan, Esraa, Surani, Salim

Journal of Community Hospital Internal Medicine Perspectives | September 3, 2023 | Volume: 13 | Issue: 5 | Pages: No page available

10.55729/2000-9666.1219 | PMID 37868681 Get It

Eosinophilic granulomatosis with polyangiitis (EGPA) also referred to as Churg-Strauss syndrome is a rare vasculitis of the small to medium vessels. We present a rare case of acute coronary artery dissection brought on by EGPA, which generally has a poor prognosis. A 41-year-old male with history of bronchial asthma presented to the emergency room with a 2-week history of dyspnea, cough with clear phlegm, and fever. For the past eight months he had experienced episodes with similar symptoms relieved by steroids. CT chest showed bilateral upper lobe patchy opacities with extensive workup for infectious etiology being negative. He had peripheral eosinophilia with sinusitis. He had acute coronary syndrome and Coronary angiogram showed Right coronary artery dissection. After making a diagnosis of EGPA based on American college of Rheumatology criteria, he was successfully treated with high dose immunosuppression. Coronary artery dissection is a fatal and uncommon complication of EGPA which is usually diagnosed postmortem. Early recognition of this condition ante mortem and aggressive treatment can be lifesaving as demonstrated in our case.
Review article: Elobixibat: a novel treatment for chronic constipation
Khanna, Lehar, Camilleri, Michael

Alimentary Pharmacology & Therapeutics | September 2, 2023 | Volume: 53 | Issue: 2 | Pages: 234-242

10.1111/apt.16143 | PMID 33296518 Get It

Summary Background A subset of patients with chronic constipation has associated slow colonic transit and reduced faecal bile acid excretion. In addition to traditional approaches to treat chronic constipation, a novel therapeutic option is to increase the colonic concentration of intraluminal bile acids. This can be achieved through inhibition of the ileal bile acid transporter. Aim To evaluate the evidence for efficacy and safety of an ileal bile acid transport inhibitor in the treatment of chronic constipation Methods We reviewed published literature on elobixibat, based on a PubMed search. Results Elobixibat is a novel ileal bile acid transport inhibitor that has demonstrated efficacy in proof of concept studies in experimental animals as well as phase 1, 2 and 3 trials in humans. Phase 4 studies have now documented that the beneficial effects are related to increase in the secretory bile acids in the colon as measured by stool bile acid content. The studies documented efficacy in patients with severe constipation, which is often associated with slow colonic transit. These changes in bile acid composition were associated with minor differences in the faecal microbiota in patients treated with elobixibat compared to placebo. Elobixibat appears to be safe. The only adverse effects of note are associated with its pharmacological actions in patients with chronic constipation,namely the induction of diarrhoea and abdominal pain. Conclusion This new class of compound appears to be safe and efficacious in the treatment of chronic constipation.
Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapy‐checkpoint inhibitory colitis. Authors' reply
Pai, Rish K. , Pai, Reetesh K., Pai, Reetesh K., Choi, Won‐Tak , Kumarasinghe, Priyanthi , Brown, Ian , Lauwers, Gregory Y. , Brown, Ian S , Pai, Reetesh K., Pai, Reetesh K., Schaeffer, David F.

Alimentary Pharmacology & Therapeutics | September 2, 2023 | Volume: 53 | Issue: 5 | Pages: 638-639

10.1111/apt.16245 | PMID 33566423 Get It

LINKED CONTENTThis article is linked to Pai et al and Buckle & Christensen papers. To view these articles, visit https://doi.org/10.1111/apt.16142 and https://doi.org/10.1111/apt.16203
Letter: elobixibatting for the long run—authors’ reply
Khanna, Lehar, Camilleri, Michael

Alimentary Pharmacology & Therapeutics | September 2, 2023 | Volume: 53 | Issue: 6 | Pages: 769-770

10.1111/apt.16290 | PMID 33599323 Get It

LINKED CONTENTThis article is linked to Khanna & Camilleri and Tobi et al papers. To view these articles, visit https://doi.org/10.1111/apt.16143 and https://doi.org/10.1111/apt.16270
Can time to deterioration in patient-reported outcomes be a surrogate for overall survival?
Mazza, Gina L. , Mazza, Gina L

JNCI: Journal of the National Cancer Institute | September 2, 2023 | Volume: 115 | Issue: 12 | Pages: 1442-1444

10.1093/jnci/djad162 | PMID 37659104 Get It

Comparison of Two Clinical Laboratory Assays for Measuring Serum Adalimumab and Antibodies to Adalimumab
Pido, Mary Therese J, Delgado, Julio C. , Willrich, Maria Alice V. , Lázár‐Molnár, Eszter , Willrich, Maria A , Lázár-Molnár, Eszter , Jain, Dharmendra

The Journal of Applied Laboratory Medicine | September 2, 2023 | Volume: 8 | Issue: 6 | Pages: 1054-1064

10.1093/jalm/jfad048 | PMID 37658801 Get It

Abstract Background Adalimumab is a fully human monoclonal antibody developed against tumor necrosis factor (TNF), used for the treatment of autoimmune and chronic inflammatory diseases. Immunogenicity to this drug may lead to therapeutic failure. Various laboratory assays are used for measuring serum adalimumab and anti-drug antibodies (ADA) to adalimumab, for therapeutic monitoring and evaluation of clinical non-responsiveness. This study compared the performance of 2 clinical assays used by different reference laboratories. Methods In total, 120 residual clinical samples were tested at both laboratories. A sandwich ELISA for adalimumab detecting free drug and a bridging ELISA capable of detecting both free and bound ADA were performed at the Mayo Clinic. A functional cell-based reporter gene assay (RGA) was used at ARUP Laboratories for measuring bioactive serum drug concentrations, and neutralizing ADA. Results Seventy-eight samples had measurable concentrations of adalimumab by both methods and yielded a correlation coefficient r = 0.93, slope = 0.886, and intercept = 0.950. Overall agreement of 92.5% was observed between the assays, with most discrepant drug results being attributed to a higher positivity rate with ELISA (8/9). One outlier positive with RGA and negative with ELISA was confirmed by LC-MS/MS to be attributed to infliximab. Overall agreement of 79.2% was observed between the ADA assays. Differences in ADA results may be due to the bridging ELISA detecting total ADA (free, drug-bound, neutralizing, and non-neutralizing), while RGA detects free, neutralizing ADA only. Conclusions Although the assays are fundamentally different, the results show significant concordance between the clinically validated tests performed in different laboratories.